Data showed that MSC therapy significantly improves liver function in patients with liver disease when analyzing the model of end-stage liver disease score, albumin, alanine aminotransferase, and total bilirubin levels, and prothrombin time [59,60,61]. Here, F2 is linked to liver disorder.